Research ArticleOriginal Article
Open Access

Evaluation of an intelligent digital platform for population management in cervical cancer screening

Xinhua Jia, Chen Gao, Xi’ao Da, Jingyi Shi, Mingyang Chen, Rufei Duan, Zhifang Li, Ruimei Feng, Yao Yang, Jiahuan Zhai, Hanyue Ding, Alex Ng and Youlin Qiao
Cancer Biology & Medicine September 2025, 22 (9) 1068-1082; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0419

References

  1. 1.↵
    2. Bray F,
    3. Laversanne M,
    4. Sung H,
    5. Ferlay J,
    6. Siegel RL,
    7. Soerjomataram I, et al.
    Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229–63.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Han B,
    3. Zheng R,
    4. Zeng H,
    5. Wang S,
    6. Sun K,
    7. Chen R, et al.
    Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4: 47–53.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Yan H,
    3. Wang Q,
    4. Qiao Y.
    Cervical cancer prevention in China: where are we now, and what’s next? Cancer Biol Med. 2024; 21: 213–7.
    OpenUrlFREE Full Text
  4. 4.↵
    2. Li Z,
    3. Liu P,
    4. Yin A,
    5. Zhang B,
    6. Xu J,
    7. Chen Z, et al.
    Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: the urgent need to address inequalities in cervical cancer. Int J Cancer. 2025; 157: 288–97.
    OpenUrlPubMed
  5. 5.↵
    World Health Organization. Regional Office for South-East Asia. Accelerating the elimination of cervical cancer as a public health problem: towards achieving 90–70–90 targets by 2030; 2022. Available from: https://iris.who.int/handle/10665/361138.
  6. 6.↵
    2. Zhang M,
    3. Wang L,
    4. Zhang X,
    5. Li C,
    6. Zhao Z,
    7. Yu M, et al.
    Cervical cancer screening rates among Chinese women – China, 2023–2024. China CDC Wkly. 2025; 7: 321–6.
    OpenUrlPubMed
  7. 7.↵
    2. Jia X,
    3. Yan H,
    4. Shi Z,
    5. Gao C,
    6. Zhai J,
    7. Ding H, et al.
    Systematic training and technological empowerment: enhancing the quality of cervical and breast cancer screening in low-resource areas of China. Gynecol Obstet Clin Med. 2024; 4: e000107.
  8. 8.↵
    2. Petersen Z,
    3. Jaca A,
    4. Ginindza TG,
    5. Maseko G,
    6. Takatshana S,
    7. Ndlovu P, et al.
    Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review. BMC Women’s Health. 2022; 22: 486.
    OpenUrlPubMed
  9. 9.
    2. Morse RM,
    3. Brown J,
    4. Ríos López EJ,
    5. Prieto BA,
    6. Kohler-Smith A,
    7. Gonzales Díaz K, et al.
    Challenges associated with follow-up care after implementation of an HPV screen-and-treat program with ablative therapy for cervical cancer prevention. BMC Public Health. 2024; 24: 2121.
    OpenUrlPubMed
  10. 10.↵
    2. Mantula F,
    3. Toefy Y,
    4. Sewram V.
    Barriers to cervical cancer screening in Africa: a systematic review. BMC Public Health. 2024; 24: 525.
    OpenUrlPubMed
  11. 11.↵
    2. Liu X,
    3. Ning L,
    4. Fan W,
    5. Jia C,
    6. Ge L.
    Electronic health interventions and cervical cancer screening: systematic review and meta-analysis. J Med Internet Res. 2024; 26: e58066.
  12. 12.
    2. Arrossi S,
    3. Paolino M,
    4. Antelo VS,
    5. Thouyaret L,
    6. Kohler RE,
    7. Cuberli M, et al.
    Effectiveness of an mHealth intervention to increase adherence to triage of HPV DNA positive women who have performed self-collection (the ATICA study): a hybrid type I cluster randomised effectiveness-implementation trial. Lancet Reg Health Am. 2022; 9: 100199.
  13. 13.
    2. Addo-Lartey AA,
    3. Bonful HA,
    4. Sefenu RS,
    5. Abagre TA,
    6. Asamoah A,
    7. Bandoh DA, et al.
    Effectiveness of a culturally tailored text messaging program for promoting cervical cancer screening in accra, Ghana: a quasi-experimental trial. BMC Womens Health. 2024; 24: 22.
    OpenUrlPubMed
  14. 14.↵
    2. Rossman AH,
    3. Reid HW,
    4. Pieters MM,
    5. Mizelle C,
    6. von Isenburg M,
    7. Ramanujam N, et al.
    Digital health strategies for cervical cancer control in low- and middle-income countries: systematic review of current implementations and gaps in research. J Med Internet Res. 2021; 23: e23350.
  15. 15.↵
    2. Huf S,
    3. Kerrison RS,
    4. King D,
    5. Chadborn T,
    6. Richmond A,
    7. Cunningham D, et al.
    Behavioral economics informed message content in text message reminders to improve cervical screening participation: two pragmatic randomized controlled trials. Prev Med. 2020; 139: 106170.
  16. 16.
    2. Firmino-Machado J,
    3. Varela S,
    4. Mendes R,
    5. Moreira A,
    6. Lunet N.
    Stepwise strategy to improve cervical cancer screening adherence (SCAN-Cervical Cancer) – automated text messages, phone calls and reminders: population based randomized controlled trial. Prev Med. 2018; 114: 123–33.
    OpenUrlPubMed
  17. 17.↵
    2. Linde DS,
    3. Andersen MS,
    4. Mwaiselage JD,
    5. Manongi R,
    6. Kjaer SK,
    7. Rasch V.
    Text messages to increase attendance to follow-up cervical cancer screening appointments among HPV-positive Tanzanian women (Connected2Care): study protocol for a randomised controlled trial. Trials. 2017; 18: 555.
    OpenUrlPubMed
  18. 18.↵
    2. Paz AA,
    3. Paula ACM,
    4. Lima AM,
    5. Castro GL,
    6. Silva MCB da Silva LT.
    Health dashboard for information management in cervical cancer screening. Rev Lat Am Enfermagem. 2025; 33: e4446.
  19. 19.↵
    2. Nessa A,
    3. Azad AK,
    4. Uddin SMN,
    5. Khan MAH,
    6. Zaman S,
    7. Khan MAS.
    Cervical cancer screening data from the case-based national electronic registry in Bangladesh. BMC Global and Public Health. 2025; 3: 34.
    OpenUrl
  20. 20.↵
    2. Almeida CM,
    3. Rodriguez MA,
    4. Skootsky S,
    5. Pregler J,
    6. Steers N,
    7. Wenger NS.
    Cervical cancer screening overuse and underuse: patient and physician factors. Am J Manag Care. 2013; 19: 482–9.
    OpenUrlPubMed
  21. 21.
    2. Fontham ETH,
    3. Wolf AMD,
    4. Church TR,
    5. Etzioni R,
    6. Flowers CR,
    7. Herzig A, et al.
    Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020; 70: 321–46.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Parekh N,
    3. Donohue JM,
    4. Men A,
    5. Corbelli J,
    6. Jarlenski M.
    Cervical cancer screening guideline adherence before and after guideline changes in Pennsylvania Medicaid. Obstet Gynecol. 2017; 129: 66–75.
    OpenUrlPubMed
  23. 23.
    2. Wright JD,
    3. Chen L,
    4. Tergas AI,
    5. Melamed A,
    6. St Clair CM,
    7. Hou JY, et al.
    Overuse of cervical cancer screening tests among women with average risk in the United States from 2013 to 2014. JAMA Netw Open. 2021; 4: e218373.
  24. 24.
    2. Franklin M,
    3. Webel A,
    4. Kaelber D,
    5. Evans J,
    6. Kelley C.
    Prevalence of cervical cancer overscreening: review of a wellness registry. Comput Inform Nurs. 2020; 38: 459–65.
    OpenUrlPubMed
  25. 25.↵
    2. Lee YW,
    3. Morgan JR,
    4. Fiascone S,
    5. Perkins RB.
    Underscreening, overscreening, and guideline-adherent cervical cancer screening in a national cohort. Gynecol Oncol. 2022; 167: 181–8.
    OpenUrlPubMed
  26. 26.↵
    2. Xia C,
    3. Basu P,
    4. Kramer BS,
    5. Li H,
    6. Qu C,
    7. Yu XQ, et al.
    Cancer screening in China: a steep road from evidence to implementation. Lancet Public Health. 2023; 8: e996–1005.
    OpenUrl
  27. 27.↵
    2. Farajimakin O.
    Barriers to cervical cancer screening: a systematic review. Cureus. 2024; 16: e65555.
  28. 28.↵
    2. Tan N,
    3. Wu Y,
    4. Li B,
    5. Chen W.
    Burden of female breast and five gynecological cancers in China and worldwide. Chin Med J (Engl). 2024; 137: 2190–201.
    OpenUrlPubMed
  29. 29.
    2. Zhang M,
    3. Zhong Y,
    4. Wang L,
    5. Bao H,
    6. Huang Z,
    7. Zhao Z, et al.
    Cervical cancer screening coverage – China, 2018–2019. China CDC Wkly. 2022; 4: 1077–82.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Zhao F,
    3. Lang J,
    4. Qiao Y,
    5. Zhu L.
    How can China achieve WHO’s 2030 targets for eliminating cervical cancer? BMJ. 2024; 386: e078641.
  31. 31.↵
    2. Zampaoglou E,
    3. Boureka E,
    4. Gounari E,
    5. Liasidi PN,
    6. Kalogiannidis I,
    7. Tsimtsiou Z, et al.
    Screening for cervical cancer: a comprehensive review of guidelines. Cancers (Basel). 2025; 17: 2072.
    OpenUrlPubMed
  32. 32.↵
    2. Lee YW,
    3. Morgan J,
    4. Fiascone S,
    5. Perkins R.
    Cervical cancer screening practices: Rates of underscreening, overscreening, and guideline-adherent screening in a national cohort (379). Gynecol Oncol. 2022; 166: S193–4.
    OpenUrl
  33. 33.↵
    2. Arrossi S,
    3. Straw C,
    4. Sanchez Antelo V,
    5. Paolino M,
    6. Baena A,
    7. Forestier M, et al.
    Implementation of WHO guidelines for cervical cancer screening, diagnosis and treatment: knowledge and perceptions of health providers from Argentina. BMC Cancer. 2024; 24: 996.
    OpenUrlPubMed
  34. 34.↵
    2. Perkins RB,
    3. Guido RL,
    4. Saraiya M,
    5. Sawaya GF,
    6. Wentzensen N,
    7. Schiffman M, et al.
    Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016–2020. J Womens Health (Larchmt). 2021; 30: 5–13.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Wu Y,
    3. Luo J,
    4. Ye D,
    5. Gao S.
    Benefits and challenges of cervical cancer screening since the implementation of the ‘two cancer’ screening programme in China: Findings from Shangyu, Zhejiang in 2019–23. J Glob Health. 2025; 15: 04064.
  36. 36.↵
    2. Gopalkrishnan K,
    3. Karim R.
    Addressing global disparities in cervical cancer burden: a narrative review of emerging strategies. Curr HIV/AIDS Rep. 2025; 22: 18.
    OpenUrl
  37. 37.↵
    2. Teoh DG,
    3. Marriott AE,
    4. Isaksson Vogel R,
    5. Marriott RT,
    6. Lais CW,
    7. Downs LS Jr., et al.
    Adherence to the 2012 national cervical cancer screening guidelines: a pilot study. Am J Obstet Gynecol. 2015; 212: 62.e1–9.
    OpenUrlCrossRefPubMed
  38. 38.
    2. Roland KB,
    3. Benard VB,
    4. Greek A,
    5. Hawkins NA,
    6. Manninen D,
    7. Saraiya M.
    Primary care provider practices and beliefs related to cervical cancer screening with the HPV test in Federally Qualified Health Centers. Prev Med. 2013; 57: 419–25.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Hawkins NA,
    3. Benard VB,
    4. Greek A,
    5. Roland KB,
    6. Manninen D,
    7. Saraiya M.
    Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers. Prev Med. 2013; 57: 641–5.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Buss LF,
    3. Levi JE,
    4. Longatto-Filho A,
    5. Cohen DD,
    6. Cury L,
    7. Martins TR, et al.
    Attendance for diagnostic colposcopy among high-risk human papillomavirus positive women in a Brazilian feasibility study. Int J Gynaecol Obstet. 2021; 152: 72–7.
    OpenUrlPubMed
  41. 41.↵
    2. Cheng D,
    3. Rieu-Werden ML,
    4. Lykken JM,
    5. Werner CL,
    6. Feldman S,
    7. Silver MI, et al.
    Assessing management of abnormal cervical cancer screening results and concordance with guideline recommendations in three US healthcare settings. Cancer Epidemiol Biomarkers Prev. 2024; 33: 912–22.
    OpenUrlPubMed
  42. 42.↵
    2. Kulkarni A,
    3. Chen L,
    4. Gockley A,
    5. Khoury-Collado F,
    6. Hou J,
    7. Clair CST, et al.
    Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals. Gynecol Oncol. 2023; 175: 53–9.
    OpenUrlPubMed
  43. 43.↵
    2. Liao Z,
    3. Zou K,
    4. Lei M,
    5. Wu Y,
    6. Yang W,
    7. Zhang Y.
    Performance of government-financed cervical cancer screening in Hunan, China, and optimization of triage strategies. J Low Genit Tract Dis. 2025; 29: 207–12.
    OpenUrlPubMed
  44. 44.↵
    2. Benites-Zapata VA,
    3. Hernandez-Bustamante EA,
    4. Acuña-Chávez LM,
    5. Escudero-Gaytan CP,
    6. Ulloque-Badaracco JR,
    7. Alarcón-Braga EA, et al.
    Colposcopy in the primary health care: a scoping review. J Prim Care Community Health. 2023; 14: 21501319231198942.
  45. 45.↵
    2. Ji L,
    3. Yao Y,
    4. Yu D,
    5. Chen W,
    6. Yin S,
    7. Fu Y, et al.
    Performance of a full-coverage cervical cancer screening program using on an artificial intelligence- and cloud-based diagnostic system: observational study of an ultralarge population. J Med Internet Res. 2024; 26: e51477.
  46. 46.↵
    2. Reaves S,
    3. Hall KC,
    4. Stewart MW,
    5. Wentzensen N,
    6. Ferrell C,
    7. Risley C, et al.
    Evaluation of follow-up colposcopy procedures after abnormal cervical screening result across a statewide study in Mississippi. Cancer Causes Control. 2024; 35: 1487–96.
    OpenUrlPubMed
  47. 47.↵
    2. Viswanathan V,
    3. Ganeshkumar P,
    4. Selvam JM,
    5. Selvavinayagam TS.
    Referral mechanism and beneficiary adherence in cervical cancer screening program in Tiruchirappalli district, Tamil Nadu state, India, 2012–2015. Indian J Cancer. 2022; 59: 39–45.
    OpenUrlPubMed
  48. 48.↵
    2. Dong B,
    3. Zou H,
    4. Mao X,
    5. Su Y,
    6. Gao H,
    7. Xie F, et al.
    Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study. Ther Adv Med Oncol. 2021; 13: 17588359211010939.
  49. 49.↵
    2. Canfell K,
    3. Kim JJ,
    4. Brisson M,
    5. Keane A,
    6. Simms KT,
    7. Caruana M, et al.
    Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet (London, England). 2020; 395: 591–603.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords